Skip to main content

Primary Care/Hospitalist

RSS  

Articles

  • EC provision doesn’t boost unprotected sex in teens

    Does advance access to emergency contraception (EC) in adolescents lead to an increase in unprotected sex? Not according to findings from a newly published study, which indicate advance EC provision does not cause teens to have more unprotected intercourse or practice less consistent contraceptive use.
  • FDA approves HIV oral fluid-based test

    Get ready to implement new advances in your clinical setting: The Food and Drug Administration (FDA) has approved the use of oral fluid samples with a rapid HIV diagnostic test kit to provide accurate screening in as little as 20 minutes. While there are three rapid HIV testing kits now on the market, the OraQuick Rapid HIV Antibody Test is the first to get clearance for use on oral fluid samples, which bypasses the need for needlesticks or fingerpricks for blood samples.
  • Ask the Experts: Answering your questions on DMPA use and weight

    Should a woman who is obese and continues to gain weight on Depo-Provera [depot medroxyprogesterone acetate (DMPA), Pfizer, New York City] be allowed to continue its use if she so desires? Are providers contributing to the health risk of obesity by allowing a woman to do so?
  • Emergency contraception moves into mainstream

    What is the policy for providing emergency contraception (EC) at your facility? About 81% of respondents to the 2004 Contraceptive Technology Update Contraception Survey say their facilities prescribe EC on site and provide emergency contraceptive pills (ECPs) at any time, which continues a trend of strong support for the method.
  • Progress under way on the microbicide front

    Promising advances are being made on the microbicide front: U.S. funding appears imminent for microbicide research and development, a new corporate partnership has been struck with an international research group to step up testing of antiviral AIDS gels, and a number of potential candidates are moving through the research pipeline.
  • Adverse event reports spark discussions on safety of Evra contraceptive patch

    Did the office telephone lines start buzzing when the media broadcasted reports of adverse events linked to use of the transdermal contraceptive Ortho Evra? Theres no doubt that clinicians have, since those reports, fielded many questions about the safety of the patch, which has been used by about 4 million women since its November 2001 approval by the Food and Drug Administration (FDA).
  • Full December 2004 issue in PDF

  • 2004 Salary Survey Results: Family planning providers hold the line in salary and staffing levels in 2004

    Good news for family planning providers: Salary levels are reflecting a modest increase in 2004, according to the results of the annual Contraceptive Technology Update salary survey. The survey was mailed in July 2004 to 1,247 subscribers and had a response of 229, for a response rate of 18.36%.
  • Washington Watch

    The increasing federal investment in abstinence-only education is one of the more notable social policy trends of the past decade. Programs must exclusively promote abstinence and therefore cannot discuss the positive benefits of contraception or condoms, because doing so would purportedly undermine the abstinence message.
  • Tips on what to cover in an initial teen exam

    What do you cover when you conduct a teens first gynecologic exam? Understand that an adolescents initial visit may not necessarily include a pelvic examination or a Pap test, but that it should cover a wide spectrum of issues facing a young woman of reproductive age.